← Trials/Trial dossier/NCT02040987
AZD3293TQT
CompletedPhase 1AZD3293 Thorough QT Study in Healthy Male Volunteers
A Single-Center, Randomized, Double-Blinded, Placebo-Controlled, 4-way Cross-over Study to Assess the Effect of a Single Oral Dose of AZD3293 Administration on QTc Interval Compared to Placebo, Using Open-Label AVELOX (Moxifloxacin) as a Positive Control, in Healthy Male Subjects
Lead sponsor
Asset
Lanabecestat
Listed sites
1
Recruiting sites
-
Enrollment
52
actual
Study population
Alzheimer’s disease
Key I/E criteria
•Age 18-55•Male
Primary endpoint
•Effect of a single dose of AZD3293 low dose
Footprint
Where this trial recruits
Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Drug assets
Study populations
Who this study enrolls
Eligibility
Who can enroll
Inclusion criteria
1. Provision of signed, written and dated informed consent prior to any study-specific procedures
2. Healthy male subjects must be able to understand and be willing to comply with study procedures, restrictions and requirements
3. Healthy male subjects aged 18 to 55 years
4. Body weight ≥ 50 to ≤ 100 kg and body mass index (BMI) ≥19 to ≤30
5. Clinically normal findings on physical examination in relation to age, as judged by the investigator
Exclusion criteria
1. History of any clinically significant disease or disorder which may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study
2. History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs
3. History of previous or ongoing psychiatric disease/condition including psychosis, affective disorder, anxiety disorder, borderline state and personality disorder
4. History of neurologic disease, including seizures (with the exception of febrile infantile seizures), recent memory impairment or clinically significant head injury
5. History of psychotic disorder among first degree relatives
Endpoints (6)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Coverage by outcome category
Safety / tolerability / PK
3 endpointsThe safety and tolerability of AZD3293 in healthy male subjects by assessing a panel of adverse events measures
Time frame:Up to 69 days
event count, event
Plasma concentrations, AUC, Cmax and tmax of single dose AZD3293 and moxifloxacin in healthy male subjects
Time frame:Up to 69 days
time to event, event
The effect of AZD3293 on additional electrocardiogram (ECG) variables (heart rate, RR, PR, QRS, QT and QTcB)
Time frame:Up to 69 days
descriptive
Other (unclassified)
3 endpointsThe effect of a single dose of AZD3293 low dose and high dose on the change in time-matched QTcF intervals compared with placebo.
Time frame:Up to 69 days
change from baseline, improvement
The effect of a single oral dose of moxifloxacin on the changes in time-matched QTcF intervals compared with placebo.
Time frame:Up to 69 days
descriptive
The relationship between plasma concentrations of AZD3293 and changes in QTcF parameters
Time frame:Up to 69 days
concentration, descriptive
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.